Most of what we know about mRNA fits a single job description: Carry genetic instructions to the cell’s machinery so it can build proteins. That is how mRNA vaccines work, and it is the basis of nearly every mRNA therapy in development.
But in her research, Stefania Nicoli, PhD, found mRNA doing something else entirely.
Nicoli, professor of medicine (cardiovascular medicine) and of genetics at Yale School of Medicine, has now received the National Institutes of Health Director’s Pioneer Award to turn that discovery into a new kind of treatment. The award supports researchers with a record of innovation who are pursuing high-risk, high-reward ideas. It provides $700,000 per year for five years.
“The award is to create a new type of mRNA therapeutic that goes beyond protein synthesis and changes protein behavior,” Nicoli says.